Press release
Glioma Competitive Landscape 2023 (Updated)
Glioma Competitive Landscape
Key Takeaways from the Glioma Competitive Landscape Report
• DelveInsight's Glioma report depicts a robust space with 200+ Glioma companies working to develop 220+ pipeline therapies for Glioma treatment.
• The leading Glioma companies working in the market include Denovo Biopharma, AstraZeneca, Pfizer, Chimerix, Bristol-Myers Squibb, Orbus Therapeutics, Northwest Biotherapeutics, Day One Biopharmaceuticals, AiVita Biomedical, Ascletis Pharma Inc., Kazia Therapeutics, HebaBiz Biotech, Biohaven Pharmaceuticals, Vigeo Therapeutics, Hoffman-La-Roche, TVAX Biomedical, Laminar Pharmaceuticals, Kintara Therapeutics, Medicenna Therapeutics, Symphogen A/S, MimiVax, Incyte Corporation, Istari Oncology, Immunomic Therapeutics, Sanofi, Merck Sharp & Dohme LLC, Oblato Inc., GlaxoSmithKline, NuvOx Pharma, Epitopoietic Research Corporation, AnHeart Therapeutics, DNAtrix, Arog Pharmaceuticals, CANbridge Pharmaceuticals, Jiangsu Hengrui Medicine, BPGbio, Inc., BioMimetix, CNS Pharmaceuticals, Ever Supreme Bio Technology, Chia Tai Tianqing Pharmaceutical Group, CytoVac, and others.
• Promising Glioma therapies in the various stages of development include DS-1001b, Radiotherapy, Nimotuzumab, AP23573, Nimotuzumab, BLZ-100, LY2157299, Temozolomide, and others.
• December 2023: Daiichi Sankyo Co. Ltd announced a study of Phase 2 clinical trials for DS-1001b. This Phase 2 study is conducted to assess the efficacy and safety of DS-1001b in patients with chemotherapy- and radiotherapy-naive IDH1 mutated WHO grade II glioma.
• December 2023: Day One Biopharmaceuticals Inc. announced a study of Phase 3 clinical trials for DAY101 and Chemotherapeutic Agent. This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 trial to evaluate the efficacy, safety, and tolerability of DAY101 monotherapy versus standard of care (SoC) chemotherapy in patients with pediatric low-grade glioma (LGG) harboring an activating rapidly accelerated fibrosarcoma (RAF) alteration requiring front-line systemic therapy.
Request a sample and discover the recent advances in Glioma Drugs @ Glioma Competitive Landscape Report- https://www.delveinsight.com/sample-request/glioma-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
The Glioma report provides an in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition - deals values trends. The sub-segmentation is described in the Glioma report which provides company-company collaboration (licensing/partnering), company academic collaboration, and acquisition analysis in tabulated form.
Glioma Overview
Glioma is the most common form of central nervous system (CNS) neoplasm that originates from glial cells. The three types of glial cells including astrocytes, oligodendrocytes, and ependymal cells are the site of origin for brain cancer or glioma. The type of tumors that initiate in astrocytes are called astrocytoma or Glioblastoma while those tumors that start in oligodendrocytes are referred to as oligodendrogliomas.
Find out more about Glioma Analytical Perspective: In-depth Commercial Assessment @ Glioma Collaboration Analysis by Companies- https://www.delveinsight.com/sample-request/glioma-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Glioma Companies and Therapies
• Bristol-Myers Squibb: Opdivo
• Orbus Therapeutics: Eflornithine
• Northwest Biotherapeutics: DCVax-L
• Medicenna Therapeutics: MDNA55
• Adastra Pharmaceuticals: Zotiraciclib
Glioma Competitive Landscape
The Glioma competitive landscape report comprises of comparative assessment of Companies (by therapy, development stage, and technology).
Glioma Report Assessment
• Company Analysis
• Glioma Therapeutic Assessment
• Glioma Pipeline Assessment
• Inactive drugs assessment
• Glioma Unmet Needs
Learn more about the emerging Glioma Competitive Landscape @ Glioma Market Drivers and Barriers, Unmet Needs- https://www.delveinsight.com/sample-request/glioma-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Glioma Competitive Landscape Report
• Coverage- Global
• Glioma Companies- Denovo Biopharma, AstraZeneca, Pfizer, Chimerix, Bristol-Myers Squibb, Orbus Therapeutics, Northwest Biotherapeutics, Day One Biopharmaceuticals, AiVita Biomedical, Ascletis Pharma Inc., Kazia Therapeutics, HebaBiz Biotech, Biohaven Pharmaceuticals, Vigeo Therapeutics, Hoffman-La-Roche, TVAX Biomedical, Laminar Pharmaceuticals, Kintara Therapeutics, Medicenna Therapeutics, Symphogen A/S, MimiVax, Incyte Corporation, Istari Oncology, Immunomic Therapeutics, Sanofi, Merck Sharp & Dohme LLC, Oblato Inc., GlaxoSmithKline, NuvOx Pharma, Epitopoietic Research Corporation, AnHeart Therapeutics, DNAtrix, Arog Pharmaceuticals, CANbridge Pharmaceuticals, Jiangsu Hengrui Medicine, BPGbio, Inc., BioMimetix, CNS Pharmaceuticals, Ever Supreme Bio Technology, Chia Tai Tianqing Pharmaceutical Group, CytoVac, and others.
• Glioma therapies- DS-1001b, Radiotherapy, Nimotuzumab, AP23573, Nimotuzumab, BLZ-100, LY2157299, Temozolomide, and others
• Glioma Therapeutics Assessment- Product Type, Stage and Product Type, Route of Administration, Stage and Route of Administration, Molecule Type, Stage and Molecule Type
Dive deep into rich insights for new drugs for Glioma Product Developmental Activities, Visit @ Glioma Research and Development Activities- https://www.delveinsight.com/sample-request/glioma-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Glioma: Overview
4. Glioma -Analytical Perspective: In-depth Commercial Assessment
5. Competitive Landscape
6. Therapeutic Assessment
7. Glioma: Company and Product Profiles (Marketed Therapies)
8. Novartis
9. Tafinlar + Mekinist
10. Glioma: Company and Product Profiles (Pipeline Therapies)
11. Late Stage Products (Phase III)
12. Bristol-Myers Squibb
13. Opdivo
14. Drug profiles in the detailed report…..
15. Mid Stage Products (Phase II)
16. Medicenna Therapeutics
17. MDNA55
18. Drug profiles in the detailed report…..
19. Early Stage Products (Phase I/II)
20. Onxeo
21. AsiDNA
22. Drug profiles in the detailed report…..
23. Preclinical and Discovery Stage Products
24. Evgen Pharma
25. SFX-01
26. Drug profiles in the detailed report…..
27. Inactive Products
28. Glioma Unmet needs
29. Glioma Market drivers and barriers
30. Appendix
For further information on the Glioma Report @ Glioma Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/glioma-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
List of Important Links-
https://forum.omz-software.com/user/germandennydones
https://bootstrapbay.com/user/germandennydones
https://freeline.mn.co/posts/51448756
https://socialmediainuk.com/story16816595/hemophilia-market-size
https://opensocialfactory.com/story15972624/hemophilia-a-market-forecast
https://ztndz.com/story18555072/hemophilia-a-market-outlook
https://gorillasocialwork.com/story17082192/hemophilia-a-market-trends
https://socialrus.com/story16299031/hemophilia-a-market-size
https://socialmediastore.net/story16857930/hemophilia-a-market-outlook
https://bookmarksurl.com/story2025609/hemophilia-a-market-size
https://myeasybookmarks.com/story2080208/pulmonary-arterial-hypertension-market-size
https://skillcrush.mn.co/posts/51450760
https://derpyshare.mn.co/posts/51450900
https://hocplayground.mn.co/posts/51451004
https://chatclub.mn.co/posts/51451178
https://printable-calendar.mn.co/posts/51451354
https://shangwich.mn.co/posts/51451496
https://drujrake.mn.co/posts/51451820
https://healingtheinnerme.mn.co/posts/51452145
https://mydreamangels.mn.co/posts/51452294
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Glioma Competitive Landscape 2023 (Updated) here
News-ID: 3400257 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Glioma
Glioma Pipeline Therapeutics Assessment Report 2024 (Updated)
DelveInsight's, "Glioma Pipeline Insight 2024" report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in the Glioma pipeline landscape. It covers the Glioma Pipeline Drug profiles, including clinical and nonclinical stage products. It also covers the Glioma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Request a sample and discover the recent advances…
Low-Grade Glioma Therapeutics Market - Transforming Futures, Defying Low-Grade G …
Newark, New Castle, USA - The latest report from Growth Plus Reports analyzes the production, potential applications, demand, major manufacturers, and SWOT analysis of the global Low-Grade Glioma Therapeutics Market.
Low-Grade Glioma Therapeutics Market: https://www.growthplusreports.com/report/lowgrade-glioma-therapeutics-market/9187
The Low-Grade Glioma Therapeutics Market Report assists in determining the optimum distribution methods for certain products as well as possible markets for future product launches. The report also analyses the purchase and supply trends that influence the…
Adult Malignant Glioma Therapeutics Market - Defying the Tumor, Empowering Survi …
Newark, New Castle, USA - new report, titled Adult Malignant Glioma Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Adult Malignant Glioma Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Adult Malignant Glioma Therapeutics market. The report offers…
Glioma pipeline involves 150+ key companies continuously working towards develop …
DelveInsight's, "Glioma Pipeline Insight, 2023," report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in Glioma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Glioma Pipeline Report
• DelveInsight's glioma pipeline report depicts a…
Rising Number of People Diagnosed with Malignant Glioma Supports the Growth of t …
Glioma is a type of tumor that occurs in brain or spine. It is a group of brain tumor that includes oligodendrogliomas and astrocytomas. Gliomas include all types of brain tumors arising from supportive tissue of the brain. Malignant glioma is the most common type of brain tumor observed in adults globally. Collectively they contribute around 40% of the total cases diagnosed with brain tumor. In the last decade, there…
Discover Malignant Glioma Market, 2016 - 2022
Malignant glioma’s are one of the common sub-type of primary brain tumors which are highly invasive, aggressive and neurologically destructive tumors among the deadliest human cancers. Gliomas account for around 45% of primary brain tumors where children are less likely to develop the risk of gliomas. Gliomas arise from the glial cells or non-neuronal cells hence the name and the cells are supposed to provide support and protection for neurons…
